<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00513162</url>
  </required_header>
  <id_info>
    <org_study_id>2007-0370</org_study_id>
    <nct_id>NCT00513162</nct_id>
  </id_info>
  <brief_title>Valproate and Etoposide for Patients With Neuronal Tumors and Brain Metastases</brief_title>
  <official_title>Valproate (Valproic Acid) and Etoposide for Patients With Progressive, Relapsed or Refractory Neuronal Tumors and Brain Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
        -  Determine the interindividual range and median of individual maximum tolerated doses of&#xD;
           valproic acid administered as one time evening dose in conjunction with a dose oral&#xD;
           etoposide (50 mg/m2/day for children, but only 25mg/m2/day for adults to start) for four&#xD;
           different age groups.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        -  Determine the qualitative and quantitative toxicity and reversibility of toxicity of&#xD;
           valproic acid in conjunction with oral etoposide,&#xD;
&#xD;
        -  To investigate the clinical pharmacokinetics of valproic acid when given in conjunction&#xD;
           with oral etoposide,&#xD;
&#xD;
        -  To describe quality of life of patients with relapsed, or progressive central and&#xD;
           peripheral nervous system tumors when treated with oral valproic acid and etoposide,&#xD;
&#xD;
        -  To observe and describe the response pattern of progressive central nervous system&#xD;
           tumors treated with oral valproic acid and etoposide,&#xD;
&#xD;
        -  To observe and describe event free survival time and overall survival time of patients&#xD;
           with relapsed, or progressive central nervous system tumors when treated with oral&#xD;
           valproic acid and etoposide,&#xD;
&#xD;
        -  To determine if histone deacetylase activity and topoisomerase expression in lymphocytes&#xD;
           of patients is related to valproic acid levels, and&#xD;
&#xD;
        -  To determine, if the individual maximal tolerated dose (iMTD) depends on the initial&#xD;
           performance status of the patient in the beginning of the treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Drugs:&#xD;
&#xD;
      Etoposide is designed to block cell growth by breaking the DNA, which may cause the cells to&#xD;
      die.&#xD;
&#xD;
      Valproic acid was first designed as an anti-seizure medication. It was also found to change&#xD;
      cancer cells and make them more sensitive to etoposide.&#xD;
&#xD;
      Screening Tests:&#xD;
&#xD;
      Before you start treatment on this study, you will have &quot;screening tests&quot;. These tests help&#xD;
      your doctor decide if you are eligible to take part in this study.&#xD;
&#xD;
        -  Your medical history will be reviewed.&#xD;
&#xD;
        -  You will have a physical exam.&#xD;
&#xD;
        -  You will be asked how well you are able to perform the normal activities of daily living&#xD;
           (performance status evaluation).&#xD;
&#xD;
        -  You will complete a questionnaire about your activities or daily living. The&#xD;
           questionnaire will take about 5 to 10 minutes to complete.&#xD;
&#xD;
        -  Blood (about 2-3 tablespoons) will be drawn for routine tests. This routine blood draw&#xD;
           may include a pregnancy test for women who are able to have children. To be eligible to&#xD;
           take part in this study, the pregnancy test must be negative.&#xD;
&#xD;
        -  Urine may be collected to check for metabolic disease. This urine sample may include a&#xD;
           pregnancy test for women who are able to have children. To be eligible to take part in&#xD;
           this study, the pregnancy test must be negative.&#xD;
&#xD;
        -  You will have a magnetic resonance imaging (MRI) or computed tomography (CT) scan.&#xD;
&#xD;
        -  If your doctor thinks it is necessary, you may have additional blood and/or urine tests.&#xD;
&#xD;
      Dose Escalation:&#xD;
&#xD;
      When you begin the study, you will begin receiving the lowest dose level of valproic acid.&#xD;
      Every week, the dose will be increased. This will continue until the maximum tolerated dose&#xD;
      (MTD) is found. Once the MTD is found, you will continue to receive that dose level of&#xD;
      valproic acid while you are on study. However, if your doctor thinks it is necessary, this&#xD;
      dose level could be lowered.&#xD;
&#xD;
      If you are a child (less than or equal to 18 years of age), the amount of etoposide that you&#xD;
      take while on study will not change.&#xD;
&#xD;
      If you are an adult (more than 18 years of age), your will receive a low dose of etoposide&#xD;
      while the MTD of valproic acid is being found. After the MTD of valproic acid is found, your&#xD;
      dose of etoposide will be increased every week until the MTD is found. However, if your&#xD;
      doctor thinks it is necessary, this dose level could be lowered.&#xD;
&#xD;
      Study Drug Administration:&#xD;
&#xD;
      You will receive valproic acid and etoposide every evening in pill form.&#xD;
&#xD;
      If you have difficulty swallowing the pills, etoposide can be given in the evening in liquid&#xD;
      form. Valproic acid can be given in liquid form, divided in 2 doses per day, 1 in the morning&#xD;
      and 1 in the evening.&#xD;
&#xD;
      Study Visits During Dose Escalation:&#xD;
&#xD;
      While your valproic acid or etoposide medication is being increased, every week you will have&#xD;
      a physical exam and blood (about 2-3 tablespoons)and urine will be collected for routine&#xD;
      tests.&#xD;
&#xD;
      Every other month, you will have CT or MRI scans to check the status of the disease. You may&#xD;
      have these tests and procedures more often if your doctor thinks it is necessary.&#xD;
&#xD;
      Study Visits After Maximum Tolerated Dose (MTD):&#xD;
&#xD;
      Every month, you will have a physical exam, and blood (about 2-3 tablespoons) and urine will&#xD;
      be collected for routine tests.&#xD;
&#xD;
      Every other month, you will have CT or MRI scans to check the status of the disease.&#xD;
&#xD;
      Every 6 months, a portion of the blood or urine collected for routine tests will be used for&#xD;
      a pregnancy test for women who are able to have children.&#xD;
&#xD;
      -You may have these tests and procedures more often if your doctor thinks it is necessary.&#xD;
&#xD;
      Length of Study:&#xD;
&#xD;
      You may remain on study for up to 2 years. You will be taken off study if the disease gets&#xD;
      worse or intolerable side effects occur.&#xD;
&#xD;
      End-of-Study Visit:&#xD;
&#xD;
      Once you are off study, you will have an end-of-study visit. At this visit, the following&#xD;
      tests and procedures will be performed:&#xD;
&#xD;
        -  You will have a physical exam.&#xD;
&#xD;
        -  Blood (about 2-3 tablespoons) and urine will be collected for routine tests.&#xD;
&#xD;
        -  If your doctor thinks it is necessary, you will have a CT or MRI to check the status of&#xD;
           the disease.&#xD;
&#xD;
      Follow-Up:&#xD;
&#xD;
      Once you are off study, you will be contacted by telephone once a year to check the status of&#xD;
      the disease. The phone call will take 2-3 minutes.&#xD;
&#xD;
      This is an investigational study. Etoposide is FDA approved and commercially available.&#xD;
      Valproic acid is FDA approved and commercially available for the treatment of seizures. The&#xD;
      use of these drugs together is investigational. Up to 120 patients will take part in this&#xD;
      multicenter study. Up to 100 will be enrolled at M. D. Anderson.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Individual Maximal Tolerated Doses (iMTD)</measure>
    <time_frame>Continuous assessment and determination of dose-limiting toxicities with each dose level (increasing dose weekly)</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Neuroectodermal Tumor</condition>
  <condition>Brain Metastases</condition>
  <condition>Advanced Cancer</condition>
  <arm_group>
    <arm_group_label>Valproate + Etoposide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Valproate Starting Dose of 10 mg/kg By Mouth Daily. Etoposide 25 - 50 mg/m^2 By Mouth Daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valproate</intervention_name>
    <description>Starting Dose of 10 mg/kg By Mouth Daily</description>
    <arm_group_label>Valproate + Etoposide</arm_group_label>
    <other_name>Valproic Acid</other_name>
    <other_name>Depakene</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>25 - 50 mg/m^2 By Mouth Daily</description>
    <arm_group_label>Valproate + Etoposide</arm_group_label>
    <other_name>VePesid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diseases: Diagnosis of a neuroectodermal tumor of the central or peripheral nervous&#xD;
             system or a brain metastasis.&#xD;
&#xD;
          2. Disease confirmation: Patients must have a diagnosis of a malignant tumor proven by&#xD;
             the diagnostic method considered standard of care for the specific tumor.&#xD;
&#xD;
          3. Disease progression and treatment failure: Patient must have failed standard&#xD;
             front-line treatment and must not be eligible for any higher-priority therapy.&#xD;
&#xD;
          4. Negative pregnancy test for female patients between menarche and menopause is&#xD;
             required.&#xD;
&#xD;
          5. Patients must sign an informed consent indicating that they are aware of the&#xD;
             investigational nature of this study in keeping with the policies of the hospital.&#xD;
&#xD;
          6. Approval for the use of this treatment regimen by the individual's Human Rights&#xD;
             Committee or Institutional Review Board (IRB) must be obtained in accordance with the&#xD;
             individual institutional policies and the local, state, and national rules,&#xD;
             regulations and laws, is mandatory for an enrolling institution. The documentation of&#xD;
             this approval must be on file at the MDAnderson Cancer Center Pediatric Oncology&#xD;
             Trials Office prior to enrollment of any patient on study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Neurofibromatosis type I.&#xD;
&#xD;
          2. Known or suspected inborn errors of metabolism.&#xD;
&#xD;
          3. Patients who require any of the following medications are excluded from enrollment:&#xD;
             Carbamazepine, Oxcarbazepine, Primidone, Phenobarbital, Topiramate, Carbapenem&#xD;
             antibiotics (ertapenem, imipenem, meropenem), Felbamate, Isoniazid, Lamotrigine,&#xD;
             Macrolide antibiotics (clarithromycin, erythromycin, troleandomycin, azithromycin),&#xD;
             Zidovudine, Risperidone, Salicylates.&#xD;
&#xD;
          4. Patients who take antiviral medications usually targeted to treat HIV infections or&#xD;
             have clinical signs for acquired immunodeficiency syndrome (AIDS) are excluded. HIV&#xD;
             testing is not mandatory.&#xD;
&#xD;
          5. Patients who had previous chemotherapy less than three weeks (21 days) ago cannot be&#xD;
             enrolled: Patients must have been off all previous chemotherapy or radiotherapy for&#xD;
             the 3 weeks prior to initiation of study treatment and recovered from toxic effects of&#xD;
             that therapy.&#xD;
&#xD;
          6. Patients which are on a stable dose for valproic acid prior to enrolment are not&#xD;
             eligible.&#xD;
&#xD;
          7. Patients which have been treated with valproic acid or other histone deacetylase&#xD;
             inhibitors such as SAHAa or MS275 and the treatment has failed to control the tumor&#xD;
             are not eligible.&#xD;
&#xD;
          8. Patient which have been treated with oral continuous etoposide previously and the&#xD;
             treatment has failed to control the tumor are not eligible.&#xD;
&#xD;
          9. White blood cell count below 2,000/ÂµL excludes patient from enrollment.&#xD;
&#xD;
         10. Absolute neutrophil count below 700/uL excludes patient from enrollment.&#xD;
&#xD;
         11. Platelet count below 80,000 excludes patient from enrollment.&#xD;
&#xD;
         12. Pancreatitis with amylase above two times the upper normal limit excludes patient from&#xD;
             enrollment, (even in the absence of clinical signs of pancreatitis).&#xD;
&#xD;
         13. Somnolence at daytime for more than 6 hours excludes patient from enrollment&#xD;
&#xD;
         14. Bilirubin total &gt; 1.5 mg/dL excludes patient from enrollment.&#xD;
&#xD;
         15. ALT &gt; 2.5 times upper normal value excludes patient from enrollment.&#xD;
&#xD;
         16. AST &gt;2.5 x upper normal value excludes patients from enrollment.&#xD;
&#xD;
         17. Frequent vomiting or medical condition that could interfere with oral medication&#xD;
             intake (e.g., partial bowel obstruction) excludes patient from enrollment.&#xD;
&#xD;
         18. Pregnant or nursing women cannot be enrolled.&#xD;
&#xD;
         19. Women of childbearing potential who are not using an effective method of contraception&#xD;
             cannot be enrolled.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tribhawan S Vats, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>The University of Texas M.D.Anderson Cancer Center</description>
  </link>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>August 7, 2007</study_first_submitted>
  <study_first_submitted_qc>August 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2007</study_first_posted>
  <last_update_submitted>September 18, 2012</last_update_submitted>
  <last_update_submitted_qc>September 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced Cancers</keyword>
  <keyword>Brain</keyword>
  <keyword>CNS</keyword>
  <keyword>Neural</keyword>
  <keyword>Pediatrics</keyword>
  <keyword>Spinal</keyword>
  <keyword>Neuroectodermal Tumor</keyword>
  <keyword>Brain Metastases</keyword>
  <keyword>Valproate</keyword>
  <keyword>Valproic Acid</keyword>
  <keyword>Depakene</keyword>
  <keyword>Etoposide</keyword>
  <keyword>VePesid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Neuroectodermal Tumors</mesh_term>
    <mesh_term>Neuroectodermal Tumors, Primitive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Valproic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

